Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe
Lumito AB (publ) (“Lumito” or the “Company”) is this week participating in one of Europe’s leading conferences for digital pathology, image analysis, and AI-driven technologies, the Digital Pathology & AI Congress: Europe in London. The conference gathers representatives from the pharmaceutical industry, CROs, hospital laboratories, academia, and technology companies to discuss developments within digital and advanced tissue analysis.
Lumito is contributing with a poster presentation describing the Company’s technology and its potential within digital pathology. Participation enables relevant meetings with stakeholders in AI, CRO, and Pharma, and provides Lumito with opportunities to broaden its dialogue with organisations working with integrated digital imaging and precision medicine.
”The Digital Pathology & AI Congress is a well-chosen forum for presenting our technology and deepening the dialogue with stakeholders working close to the processes where our product can make a difference. Being present in London is also a concrete part of our intensified commercialisation efforts, which we can now pursue with increased momentum”, says Sanna Wallenborg, CEO of Lumito.
As the proceeds from the share issue and the recently approved grant from Region Skåne have strengthened the Company’s financial position, activities are being carried out in the areas of marketing, visibility, and partner dialogues. Participation in national and international conferences is one of the areas the Company is accelerating to support continued market introduction and commercialisation initiatives.
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Bifogade filer